Afimoxifene
Afimoxifene, also known as 4-hydroxytamoxifen, is a selective estrogen receptor modulator (SERM) that is recognized as the active metabolite of the well-known drug, tamoxifen. Unlike tamoxifen, which is typically administered orally, afimoxifene is formulated as a transdermal gel.
Development and Commercialization[edit | edit source]
Ascend Therapeutics, Inc. is the company behind the development of afimoxifene, marketing it under the trademark name TamoGel. This transdermal gel formulation provides a unique method of delivery, which may offer advantages over traditional oral administration.
Clinical Trials and Research[edit | edit source]
Afimoxifene has undergone several clinical trials to evaluate its efficacy and safety:
- Phase II Clinical Trial: A significant phase II clinical trial was conducted focusing on the potential use of afimoxifene for the treatment of cyclical mastalgia, a condition characterized by breast pain related to menstrual cycles.
- Comparative Study with Tamoxifen: A noteworthy study carried out in France included 55 women and indicated that the topical application of afimoxifene directly to the skin was as effective as orally-administered tamoxifen tablets in decelerating the growth of breast cancer. The advantages of such topical application include a significant reduction in systemic levels (by a factor of nine), which can potentially minimize the undesired side effects commonly associated with tamoxifen. A subsequent trial in the US is set to compare the outcomes of 6 weeks of afimoxifene use prior to undergoing breast cancer surgery.
Potential Benefits[edit | edit source]
One of the primary anticipated benefits of afimoxifene's topical application is a marked decrease in the systemic exposure to the drug. This could lead to a significant reduction in the side effects generally seen with tamoxifen, making the treatment more tolerable for patients.
See also[edit | edit source]
| Afimoxifene Resources | |
|---|---|
|
 |
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
